TECHNICAL ADVISORY BOARD

Jim Deeds is a Senior Technical Leader in the Oncology Targets and Biomarkers group at Novartis Institutes for Biomedical Research (NIBR). He is responsible for the development of pathology imaging and information systems for research oncology pathology in Cambridge and technical leader for NIBR's effort to integrate their global oncology research pathology sites. Prior to his work at Novartis, Jim spent 10 years at Millennium Pharmaceuticals (MPI) where he established the companys molecular pathology laboratory and was lead scientist for the identification and characterization of markers of cervical cancer aggressiveness. He led the clinical validation, assay development and product launch support for the metastatic melanoma marker Melastatin and was lead scientist for the clinical validation of slide-based pharmacogenomic markers for Velcade. His group was responsible for the development and implementation of quantitative imaging methods for all slide based pre-clinical and clinical studies at MPI. He is a graduate of MIT (1989) where he earned a degree in Brain and Cognitive Science.

Michael Feldman's professional interests revolve around the development, integration and adoption of information technologies in the discipline of Pathology. One of his main areas of interest within this broad discipline has been in the field of digital imaging. He has been exploring pathology imaging on several fronts including interactions between pathology/radiology (High resolution MRI imaging of prostate cancer), development and utilization of computer assisted diagnostic algorithms for machine vision in prostate and breast cancer (Collaboration with Dr. Anant Madhabushi Rutgers) and automated immunohistochemical scoring of TMA (Collaboration with Dr. David Foran at UMDNJ). His newest area of investigation is the use of multispectral imaging for the analysis of multicolor immunohistochemistry and immunoflourescence and the development of a quantitative system for scoring and analyzing at a cytometric level, multicolor immunostaining on surgical pathology slides.

Cliff Slaughterbeck is the Engineering Manager at the Allen Institute for Brain Science. He received dual B.S. degrees from the University of Idaho in Physics and Mathematics in 1987. He earned his Ph.D. in Physics from the University of Washington in 1996. Following graduate school, Cliff joined Microstar Laboratories in Bellevue, WA, where he worked in the data acquisition field as an applications engineer and systems integration manager. He left Microstar to be an embedded systems software engineer at Index Sensors and Controls, where he co-developed a software-controlled programmable temperature switch that was awarded a US patent. Cliff then joined Intelligent Ion, Inc. as an embedded software engineer writing software for a portable mass spectrometer. Since his arrival at the Allen Institute in 2004, he worked on the design and operation of the Institute’s high-throughput microscopy laboratory and assisted with the design of the Institute’s two-photon microscopy lab. Additionally, Cliff’s group manages the acquisition, design and maintenance of all equipment at the Allen Institute. He is a member of the Association for Laboratory Automation and IEEE.

James A Thompson M.D. Ph.D. currently serves as a Senior Hematopathologist at Genoptix Inc., Carlsbad, CA; Medical Director of Ambry Genetics, Aliso Viejo, CA; and President and Medical Director of Pathogenesys LLC, San Juan Capistrano, CA. Dr. Thompson previous served in both Management and Clinical positions at USLabs, Irvine, CA; Oncotech, Tustin, CA; Impath, Los Angeles, CA; and Meyer Pharmaceuticals, Irvine, CA. He currently holds a Volunteer Faculty position at UCIrvine College of Medicine and served as the Directors of Hematopathology and Immunotherapy Laboratories at UCIMC. Dr. Thompson holds a B.S., M.D. and Ph.D. degrees in biological and medical sciences from the University of California, Irvine and underwent Internship, Pathology Residency and Molecular Pathology Fellowship at Stanford University and Hematopathology Fellowship at UCIrvine College of Medicine.